Confronto
Enfuvirtid vs. Goserelin
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
159519-65-0
65807-02-5
Peso molecolare
4491.88 g/mol
1269.43 g/mol
Emivita
nessun dato
4.2 h
Sequenza
nessun dato
pGlu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-Azgly-NH2Meccanismo d'azione
Enfuvirtid
Enfuvirtide binds the first heptad-repeat region (HR1) of the gp41 subunit of the HIV envelope protein. This prevents the conformational change required for fusion of the viral and cell membranes — the virus cannot enter the cell.
Goserelin
As a GnRH agonist, goserelin binds to the GnRH receptors of the pituitary gland. Initial stimulation transiently raises luteinizing hormone (LH) and follicle-stimulating hormone (FSH). With continuous receptor occupancy, however, the receptors become desensitized and down-regulated, which reduces LH and FSH secretion and consequently the production of testosterone or estrogen. This mechanistic relationship is documented in the pharmacological literature.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
1
4
di cui sull'uomo
1
4
Effetti registrati
2
3
Contraddizioni aperte
0
1
Eventi avversi documentati
1
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Enfuvirtid and Goserelin?
- Enfuvirtid is classified as "Ricerca (altro)", while Goserelin is classified as "Ricerca (altro)". Enfuvirtid: Enfuvirtide is a synthetic 36-amino-acid peptide and the first HIV-1 fusion inhibitor. It binds the HR1 region of the viral envelope protein gp41, blocking viral entry into the cell. Approved for treatment-experienced HIV patients. Goserelin: Goserelin is a synthetic decapeptide and an agonist of gonadotropin-releasing hormone (GnRH). The medical literature describes it as a hormonal agent that suppresses the release of sex hormones through sustained receptor stimulation. Regulatory-approved indications include prostate cancer, advanced breast cancer, endometriosis, and endometrial thinning, among others. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Enfuvirtid or Goserelin?
- The highest available evidence level is "RCT sull'uomo" for Enfuvirtid and "RCT sull'uomo" for Goserelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Enfuvirtid and Goserelin in Germany and the United States?
- Germania: Enfuvirtid — Su prescrizione, Goserelin — Su prescrizione. Stati Uniti: Enfuvirtid — Su prescrizione, Goserelin — Su prescrizione. These are factual summaries with source and review date on the individual pages.